文献速递肥胖与代谢综合征糖尿病

利拉鲁肽对超重或肥胖高危心血管风险成人内脏及异位脂肪的影响:一项随机双盲安慰剂对照临床试验

Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-08-03

结论认为利拉鲁肽可显著降低内脏脂肪,可能是既往试验中心血管获益的机制之一。

要点

  • 胃肠道不良事件在利拉鲁肽组更常见(47% vs 13%)。

核心结论

  • 内脏脂肪减少可能是利拉鲁肽在既往2型糖尿病试验中观察到心血管获益的机制之一。

研究设计与样本

  • 随机、双盲、安慰剂对照、4期、单中心试验,纳入社区成人,BMI≥30 kg/m²或BMI≥27 kg/m²伴代谢综合征且无糖尿病。
  • 共185例随机(利拉鲁肽92例,安慰剂93例),128例纳入最终分析(利拉鲁肽73例,安慰剂55例)。

主要发现

  • 效应在年龄、性别、种族-民族、BMI和基线糖尿病前期亚组中似乎一致。
  • 最常见不良事件为胃肠道相关(利拉鲁肽组43/92[47%],安慰剂组12/93[13%])和上呼吸道感染(利拉鲁肽组10/92[11%],安慰剂组14/93[15%])。

临床怎么用

  • 使用利拉鲁肽时需关注胃肠道不良反应。

局限性

  • 单中心试验,样本量有限,最终分析仅128例。
  • 参与者以女性为主(92%),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes in obesity. We aimed to evaluate the effects of injectable liraglutide 3·0 mg daily on body fat distribution in adults with overweight or obesity without type 2 diabetes at high cardiovascular disease risk. METHODS: In this randomised, double-blind, placebo-controlled, phase 4, single centre trial, we enrolled community-dwelling adults, recruited from the University of Texas Southwestern Medical Center, with BMI of at least 30 kg/m2 or BMI of at least 27 kg/m2 with metabolic syndrome but without diabetes and randomly assigned them, in a 1:1 ratio, to 40 weeks of treatment with once-daily subcutaneous liraglutide 3·0 mg or placebo, in addition to a 500 kcal deficient diet and guideline-recommended physical activity counselling. The primary endpoint was percentage reduction in visceral adipose tissue (VAT) measured with MRI. All randomly assigned participants with a follow-up imaging assessment were included in efficacy analyses and all participants who received at least one dose of study drug were included in the safety analyses. The trial is registered on ClinicalTrials.gov: NCT03038620. FINDINGS: Between July 20, 2017 and Feb 21, 2020 from 235 participants assessed for eligibility, 185 participants were randomly assigned (n=92 liraglutide, n=93 placebo) and 128 (n=73 liraglutide, n=55 placebo) were included in the final analysis (92% female participants, 37% Black participants, 24% Hispanic participants, mean age 50·2 years (SD 9·4), mean BMI 37·7 kg/m2). Mean change in VAT over median 36·2 weeks was -12·49% (SD 9·3%) with liraglutide compared with -1·63% (SD 12·3%) with placebo, estimated treatment difference -10·86% (95% CI -6·97 to -14·75, p<0·0001). Effects seemed consistent across subgroups of age, sex, race-ethnicity, BMI, and baseline prediabetes. The most frequently reported adverse events were gastrointestinal-related (43 [47%] of 92 with liraglutide and 12 [13%] of 93 with placebo) and upper respiratory tract infections (10 [11%] of 92 with liraglutide and 14 [15%] of 93 with placebo). INTERPRETATION: In adults with overweight or obesity at high cardiovascular disease risk, once-daily liraglutide 3·0 mg plus lifestyle intervention significantly lowered visceral adipose tissue over 40 weeks of treatment. Visceral fat reduction may be one mechanism to explain the benefits seen on cardiovascular outcomes in previous trials with liraglutide among patients with type 2 diabetes. FUNDING: NovoNordisk.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Neeland IJ, Marso SP, Ayers CR, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021. PMID: 34358471. doi:10.1016/S2213-8587(21)00179-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。